Abstract No. 710 Can an intratumoral DNA-encoded immunotherapeutic device platform currently used in the management of cutaneous lesions be scaled in size to function in the treatment of visceral tumors through image-guided techniques?

The mobilization of the immune system as a therapeutic strategy has emerged as a transformative approach to the treatment of cancer. Intratumoral injection of plasmid IL-12, tavokinogene telseplasmid (TAVO), and co-localized reversible electroporation has demonstrated safe and promising results in the nearly 200 patients enrolled in trials for melanoma, breast cancer, and SCCHN. This current delivery platform uses an applicator capable of reaching lesions no more than 1.5 cm at or below the skin.
Source: Journal of Vascular and Interventional Radiology : JVIR - Category: Radiology Authors: Tags: Scientific Traditional Poster Source Type: research